Peregrine shares blasted after trial 'discrepancies' discredit lung cancer data

Two weeks ago shares of Peregrine Pharmaceuticals ($PPHM) skyrocketed on the upbeat survival data it released from a mid-stage study of its lung cancer drug bavituximab. This morning the share price disintegrated after the biotech said the data were unreliable, blaming an unnamed outsourcer for "major discrepancies" found in the distribution of clinical trial supplies used in the study.

Within minutes Peregrine's shares tumbled 80%.

"As part of the trial's execution, Peregrine contracted with independent third-party contractors to execute treatment group assignments and oversee clinical trial material coding and distribution according to established procedures," Peregrine announced in a release. "A subsequent review of information has determined that the source of these discrepancies appear to have been associated with the independent third-party contracted to code and distribute investigational drug product."

As FierceBiotech reported on September 7, Peregrine had reported that non-small cell lung cancer patients in the experimental drug arm lived for a median 12.1 months. In the chemo arm, the survival rate was about half that. But the progression-free survival rate was only 4.2 months, causing a number of analysts to question the data on Twitter as they compared a high OS rate with a low PFS. Peregrine enrolled 121 patients for the study. Peregrine also took a beating back in March, when the PFS rate it tracked on bavituximab came close to the rate tracked in the placebo group.

The biotech said it became aware of the discrepancies in the study as it began to prepare for a post-study sit-down with the FDA. Peregrine had been investigating bavituximab as a potential second-line treatment for non-small cell lung cancer. And Peregrine added that the dark cloud now hanging over its Phase II trial would have no impact on other ongoing studies.

- here's the press release

Related conversation on  Twitter :

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.